CONSORT-Equity 2017 extension and elaboration for better reporting of health equity in randomised trials

被引:106
|
作者
Welch, Vivian A. [1 ,2 ]
Norheim, Ole F. [3 ,4 ]
Jull, Janet [5 ]
Cookson, Richard [6 ]
Sommerfelt, Halvor [3 ,7 ]
Tugwell, Peter [8 ]
机构
[1] Bruyere Res Inst, Methods Ctr, Ottawa, ON, Canada
[2] Univ Ottawa, Sch Epidemiol Publ Hlth & Prevent Med, Ottawa, ON, Canada
[3] Univ Bergen, Dept Global Publ Hlth & Primary Care, Ctr Intervent Sci Maternal & Child Hlth CISMAC, Bergen, Norway
[4] Harvard TH Chan Sch Publ Hlth, Dept Global Hlth & Populat, Bergen, Norway
[5] Univ Ottawa, Ottawa Hosp Res Inst, Ottawa, ON, Canada
[6] Univ York, Ctr Hlth Econ, York YO10 5DD, N Yorkshire, England
[7] Norwegian Inst Publ Hlth, Oslo, Norway
[8] Univ Ottawa, Dept Med, Ottawa, ON, Canada
来源
关键词
D O I
10.1136/bmj.j5085
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
We outline CONSORT-Equity 2017 reporting standards, an extension to the CONSORT (Consolidated Standards of Reporting Trials) statement that aims to improve the reporting of intervention effects in randomised trials where health equity is relevant. Health inequities are unfair differences in health that can be avoided by reasonable action. We defined a randomised trial where health equity is relevant as one that assesses effects on health equity by evaluating an intervention focused on people experiencing social disadvantage or by exploring the difference in the effect of the intervention between two groups (or as a gradient across more than two groups) experiencing different levels of social disadvantage, or both. We held a consensus meeting with diverse potential users from high, middle, and low income countries, including knowledge users such as patients and methodologists. We discussed evidence for each proposed extension item from empirical studies, reviews, key informant interviews, and an online survey, aiming to improve clarity of reporting without imposing undue burden on authors. The new guidance contains equity extensions to 16 items from CONSORT 2010 plus one new item on research ethics reporting, with examples of good practice and a brief explanation and elaboration for each. Widespread uptake of this guidance for the reporting of trials where health equity is relevant will make it easier for decision makers to find and use evidence from randomised trials to reduce unfair inequalities in health.
引用
收藏
页数:15
相关论文
共 50 条
  • [31] Reporting of surrogate endpoints in randomised controlled trial reports (CONSORT-Surrogate): extension checklist with explanation and elaboration
    Manyara, Anthony Muchai
    Davies, Philippa
    Stewart, Derek
    Weir, Christopher J.
    Young, Amber E.
    Blazeby, Jane
    Butcher, Nancy J.
    Bujkiewicz, Sylwia
    Chan, An -Wen
    Dawoud, Dalia
    Offringa, Martin
    Ouwens, Mario
    Hrobjartssson, Asbjorn
    Amstutz, Alain
    Bertolaccini, Luca
    Bruno, Vito Domenico
    Devane, Declan
    Faria, Christina D. C. M.
    Gilbert, Peter B.
    Harris, Ray
    Lassere, Marissa
    Marinelli, Lucio
    Markham, Sarah
    Powers III, John
    Rezaei, Yousef
    Richert, Laura
    Schwendicke, Falk
    Tereshchenko, Larisa G.
    Thoma, Achilles
    Turan, Alparslan
    Worrall, Andrew
    Christensen, Robin
    Collins, Gary S.
    Ross, Joseph S.
    Taylor, Rod S.
    Ciani, Oriana
    BMJ-BRITISH MEDICAL JOURNAL, 2024, 386
  • [32] CONSORT for reporting randomised trials in journal and conference abstracts
    Hopewell, Sally
    Clarke, Mike
    Moher, David
    Wager, Elizabeth
    Middleton, Philippa
    Altman, Douglas G.
    Schulz, Kenneth F.
    LANCET, 2008, 371 (9609): : 281 - 283
  • [33] Improving the reporting of randomised trials: the CONSORT Statement and beyond
    Altman, Douglas G.
    Moher, David
    Schulz, Kenneth F.
    STATISTICS IN MEDICINE, 2012, 31 (25) : 2985 - 2997
  • [34] Reporting quality of life in clinical trials: a CONSORT extension
    Calvert, Melanie
    Blazeby, Jane
    Revicki, Dennis
    Moher, David
    Brundage, Michael
    LANCET, 2011, 378 (9804): : 1684 - 1685
  • [35] Improving the reporting of pragmatic trials: an extension of the CONSORT statement
    Zwarenstein, Merrick
    Treweek, Shaun
    Gagnier, Joel J.
    Altman, Douglas G.
    Tunis, Sean
    Haynes, Brian
    Oxman, Andrew D.
    Moher, David
    BMJ-BRITISH MEDICAL JOURNAL, 2008, 337 : 1223 - 1226
  • [36] Guidance for protocol content and reporting of factorial randomised trials: explanation and elaboration of the CONSORT 2010 and SPIRIT 2013 extensions
    Kahan, Brennan C.
    Juszczak, Edmund
    Beller, Elaine
    Birchenall, Megan
    Chan, An-Wen
    Hall, Sophie
    Little, Paul
    Fletcher, John
    Golub, Robert M.
    Goulao, Beatriz
    Hopewell, Sally
    Islam, Nazrul
    Zwarenstein, Merrick
    Elbourne, Diana
    Montgomery, Alan
    BMJ-BRITISH MEDICAL JOURNAL, 2025, 388
  • [37] CONSORT 2010 statement: extension to randomised crossover trials
    Dwan, Kerry
    Li, Tianjing
    Altman, Douglas G.
    Elbourne, Diana
    BMJ-BRITISH MEDICAL JOURNAL, 2019, 366
  • [38] Consort 2010 statement: extension to cluster randomised trials
    Campbell, Marion K.
    Piaggio, Gilda
    Elbourne, Diana R.
    Altman, Douglas G.
    BMJ-BRITISH MEDICAL JOURNAL, 2012, 345
  • [39] The Revised CONSORT Statement for Reporting Randomized Trials: Explanation and Elaboration (2001)
    Altman, Douglas G.
    Schulz, Kenneth F.
    Moher, David
    Egger, Matthias
    Davidoff, Frank
    Elbourne, Diana
    Tzsche, Peter C. G.
    Lang, Thomas
    RATIONAL PHARMACOTHERAPY IN CARDIOLOGY, 2010, 6 (06) : 929 - 937
  • [40] Health Equity and Decentralized Trials
    Dahne, Jennifer
    Hawk, Larry W., Jr.
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2023, 329 (23): : 2013 - 2014